Y Intercept Hong Kong Ltd Makes New Investment in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Y Intercept Hong Kong Ltd bought a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 130,146 shares of the company’s stock, valued at approximately $2,868,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Smithfield Trust Co boosted its holdings in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after acquiring an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $50,000. Ameliora Wealth Management Ltd. bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $66,000. Venturi Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at about $60,000. Finally, Farther Finance Advisors LLC increased its position in shares of Teva Pharmaceutical Industries by 273.5% during the third quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock valued at $82,000 after buying an additional 3,323 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 0.0 %

Shares of NYSE:TEVA opened at $16.75 on Tuesday. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The stock has a fifty day simple moving average of $19.93 and a two-hundred day simple moving average of $18.50. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80. The stock has a market capitalization of $18.97 billion, a price-to-earnings ratio of -11.55, a PEG ratio of 1.44 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on TEVA shares. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. UBS Group reduced their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $23.57.

Insider Activity

In related news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.